Opinion: US and EU reviews of blood clots and J&J’s Covid vaccine show why a transparent process matters
When the CDC’s top advisory committee met last week to review whether a handful of very rare but potentially fatal blood clots with low platelets might be linked to J&J’s Covid-19 vaccine, the assumption was that the committee would, at the very least, follow its own agenda and vote on whether to wait for more data, or make interim age- or risk-based recommendations for the vaccine.
Instead, the committee did neither, punting its vote until this Friday when it can hold a longer discussion with the latest data. None of the ACIP members raised major concerns with the decision, or lack thereof, despite some calls to not pause the vaccine indefinitely.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters